Amanta Healthcar Stock Price Today (NSE: AMANTA)
Fundamental Score
Amanta Healthcar Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Amanta Healthcar share price today is ₹115.32, down 4.86% on NSE/BSE as of 19 June 2026. Amanta Healthcar (AMANTA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹408.81 (Cr). The 52-week high for AMANTA share price is ₹154.40 and the 52-week low is ₹92.00. At a P/E ratio of 40.16x, AMANTA is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.99% and a debt-to-equity ratio of 0.88.
Amanta Healthcar Share Price Chart — NSE/BSE Historical Performance
Amanta Healthcar share price chart: -1.88% return over the past month. 52-week high ₹154.40, 52-week low ₹92.00.
Amanta Healthcar — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹120.90 | ₹122.30 | ₹114.05 | ₹115.32 | 3.56L (Cr) | |
| ₹125.52 | ₹129.00 | ₹119.70 | ₹121.21 | 1.32L (Cr) | |
| ₹131.30 | ₹134.00 | ₹122.93 | ₹125.51 | 2.23L (Cr) | |
| ₹134.78 | ₹134.78 | ₹131.20 | ₹131.80 | 60.66K (Cr) | |
| ₹129.15 | ₹134.41 | ₹129.15 | ₹133.25 | 1.34L (Cr) | |
| ₹130.09 | ₹135.00 | ₹129.32 | ₹132.27 | 1.25L (Cr) | |
| ₹126.61 | ₹131.99 | ₹125.12 | ₹130.09 | 47.65K (Cr) | |
| ₹127.62 | ₹129.10 | ₹125.41 | ₹126.24 | 46.51K (Cr) | |
| ₹131.00 | ₹131.00 | ₹125.50 | ₹126.35 | 88.97K (Cr) | |
| ₹126.00 | ₹135.00 | ₹126.00 | ₹132.36 | 1.01L (Cr) |
Amanta Healthcar — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹125.52 | ₹129.00 | ₹114.05 | ₹115.32 | -8.13% | |
| ₹131.13 | ₹146.78 | ₹122.00 | ₹125.51 | -4.29% | |
| ₹101.92 | ₹140.25 | ₹99.87 | ₹131.13 | +28.66% | |
| ₹99.71 | ₹102.50 | ₹92.00 | ₹99.81 | +0.10% | |
| ₹103.80 | ₹110.65 | ₹100.00 | ₹102.95 | -0.82% | |
| ₹109.00 | ₹115.00 | ₹98.25 | ₹103.33 | -5.20% | |
| ₹104.50 | ₹117.12 | ₹97.75 | ₹109.06 | +4.36% | |
| ₹121.99 | ₹124.89 | ₹99.99 | ₹106.24 | -12.91% | |
| ₹132.60 | ₹140.00 | ₹119.50 | ₹121.99 | -8.00% | |
| ₹145.98 | ₹154.40 | ₹133.71 | ₹136.36 | -6.59% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Micro-cap pharma with stretched valuation and weak long-term sales growth; avoid until fundamentals improve.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Amanta Healthcare saw mixed activity. A promoter increased their stake with open market purchases worth in late March. Bandhan Mutual Fund increased its stake above 5%. However, the stock was downgraded to 'Sell' by MarketsMOJO on April 7, 2026, citing weak long-term fundamentals despite recent quarterly improvements.
CORE STORY (THE REAL GAME)
Amanta is being priced as a high-growth, margin-expanding pharma player, leveraging its SteriPort technology in the IV fluids market. The real game is whether they can sustain this growth and margin profile in a competitive landscape.
- Promoter buying provides short-term support
- Q3 FY26 showed improved profitability
- SteriPort capacity expansion is expected to drive growth
- Significant order wins in export markets
- Faster-than-expected SteriPort adoption
- Debt reduction
- Micro/SME cap: liquidity risk
- High P/E ratio relative to industry
- Negative 5-year sales CAGR
Promoter increased stake, but FII/DII holdings are stable.
Indian pharma sector is seeing increased investment, but competition is intense.
No major news found after live search.
Yes - Free Cash Flow 5Y: ₹178.99 Cr
Next 3-6 months hinge on SteriPort adoption and export performance. Watch for Q4 results and any guidance on future growth.
Primary Thesis Risk
Failure to achieve sustained sales growth and margin expansion will lead to a significant correction.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Amanta Healthcar Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Amanta Healthcar Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AMANTA across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (21.51%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Excellent EPS Growth (20.32% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (20.68% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Cash Generation (₹178.99 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (63.56%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 40.16x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-17.26%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Interest Coverage (1.53x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Amanta Healthcar vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Amanta Healthcar with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Amanta HealthcarAmanta Healthca...Selected✓ AMANTA • 544502 | 44.5/100 | ₹115.32₹115 | ₹408.81₹408.81 | 40.16Average 40.2 Average | 12.99%Average 12.99% Average | 14.80%Average 14.80% Average | 0.88Good 0.9 Good | 20.68%Excellent 20.68% Excellent | 8.30%Good 8.30% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Amanta Healthcar Quarterly Performance
Latest quarterly metrics for AMANTA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
6.23%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-17.26%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
8.30%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
20.68%
Compounded annual net profit growth over 5 years
Amanta Healthcar Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AMANTA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Amanta Healthcar Financial Statements
Annual income statement, balance sheet and cash flow for Amanta Healthcar (AMANTA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Amanta Healthcar
About AMANTA (Amanta Healthcar)
Amanta Healthcar is a global pharmaceutical enterprise committed to advancing health and wellness through the development, production, and distribution of high-quality sterile liqu...id products. They are dedicated to crafting a portfolio of essential pharmaceuticals designed to meet the evolving needs of patients across diverse geographical regions. Amanta's operations are underpinned by a strong commitment to research and development, focusing on innovative formulations and delivery systems to improve therapeutic outcomes. Their core values revolve around safety, efficacy, and accessibility, ensuring that their products reach those who need them most, regardless of their location. Through unwavering dedication to quality and patient-centricity, Amanta strives to be a trusted partner in global healthcare, making a tangible difference in the lives of individuals and communities worldwide. Amanta Healthcar specializes in the manufacture of a comprehensive range of parenteral solutions, meticulously produced under stringent quality control standards. Their state-of-the-art manufacturing facilities are equipped to handle various product formats, catering to the specific requirements of healthcare providers and patients. The company's dedication to sterile manufacturing techniques ensures the safety and integrity of its products, meeting and exceeding international regulatory requirements. Amanta's portfolio includes a diverse array of large-volume parenterals, small-volume parenterals, and specialized delivery systems, such as nipple-head and steriport configurations. This broad product offering positions them as a versatile supplier of essential medications for hospitals, clinics, and other healthcare institutions globally. Amanta Healthcar's commitment extends beyond pharmaceutical manufacturing, encompassing the development and production of critical medical devices and fluid therapies. This expanded focus reflects their understanding of the holistic needs of healthcare providers and their dedication to providing comprehensive solutions. Their fluid therapy segment focuses on intravenous fluids, essential for hydration, electrolyte balance, and medication delivery. By integrating medical devices and fluid therapies into their portfolio, Amanta Healthcar demonstrates a dedication to innovation and comprehensive healthcare solutions. This strategic approach allows them to offer a more integrated and streamlined approach to patient care, further solidifying their position as a valuable partner in the global healthcare landscape.
Company Details
Key Leadership
AMANTA Share Price: Frequently Asked Questions
What is the current share price of Amanta Healthcar?
Amanta Healthcar (AMANTA) trades at ₹115.32 on NSE and BSE. Market cap ₹408.81 (Cr). Educational data only.
What is the P/E ratio of Amanta Healthcar?
Amanta Healthcar has a P/E of 40.16x vs industry average 31.77x.
What is the Bull Run score for Amanta Healthcar?
Amanta Healthcar has a Bull Run score of 44.5/100 based on 25+ financial parameters.
Does Amanta Healthcar pay dividends?
Amanta Healthcar has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Amanta Healthcar?
Amanta Healthcar has ROE of 12.99%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Amanta Healthcar?
Amanta Healthcar has debt-to-equity of 0.88.
Is Amanta Healthcar a good investment?
Bull Run gives Amanta Healthcar a score of 44.5/100. This is not investment advice — consult a SEBI-registered advisor.